NEW YORK, NY--(Marketwire - Nov 16, 2011) - The case for increased stem cell funding is growing by the day as the potentially lifesaving effects of regenerative medicine continue to be revealed. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Aastrom Biosciences, Inc. (NASDAQ: [ ASTM ]) and NeoStem, Inc. (NYSE Amex: [ NBS ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/ASTM ]
[ www.bedfordreport.com/NBS ]

Ground breaking studies out of Japan earlier this month showed the vast reach of stem cell medicine. A research team at Japan's RIKEN Center for Developmental Biology successfully used stem cells to synthesize a fully functioning organ entirely from scratch. The team somehow managed to take mouse stem cells and transformed them into a working pituitary gland, which is a small organ that lives at the base of your brain and produces hormones that help you grow.

The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous analyst reports and industry newsletters.

Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.

NeoStem, Inc. engages in the development of stem cell-based therapies for anti-aging initiatives and building a network of adult stem cell collection centers in the United States and China. Last month NeoStem consummated the acquisition of Amorcyte, Inc., taking ownership of a strong patent portfolio covering the use of hematopoietic stem cells for treatment of cardiac ischemia. Amorcyte's lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction.

Aastrom Biosciences Inc said on Monday its cell therapy Ixmyelocel-T proved safe in a mid-stage clinical trial and helped delay some symptoms of critical limb ischemia, a severe form of peripheral arterial disease, in patients who have no real alternatives. The company plans to begin a late-stage trial of the therapy within the next few weeks, according to its chief executive, Timothy Mayleben.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ]